{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:21:31Z","timestamp":1792034491132,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fujian Children\u2019s Hospital Cultivation Project","award":["YP202401"],"award-info":[{"award-number":["YP202401"]}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2023Y9211"],"award-info":[{"award-number":["2023Y9211"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive peripheral T-cell lymphoma that is prone to early progression and recurrence and has a poor overall prognosis. Notably, early mortality (EM) and risk factors for AITL are currently unclear.\u00a0We performed a retrospective analysis of AITL data from 2000 to 2021 in the Surveillance, Epidemiology, and End Results databases. Early death was defined as death within two years from the date of diagnosis. Histograms and pie charts were used to present the distribution of overall early mortality (O-EM) and lymphoma-specific early mortality (LS-EM). Cox regression model was used to screen the risk factors. Cumulative event rate curves were used to analyze the effect of treatment on EM.\u00a0In total, 2,413 patients diagnosed with AITL were included in this study. Among the deceased patients, the O-EM was 46.6%, with an LS-EM of 39.7%. EM increased significantly with age, was higher among white person than among other racial groups, and was higher among males than among females. Significant independent risk factors for both O-EM and LS-EM included sex, age, SEER historic stage, radiation therapy, and chemotherapy. The combination of chemotherapy and radiotherapy can decrease O-EM and LS-EM rates in males, aged 40\u201369 years, and patients with localized and regional SEER historic stages.\u00a0AITL demonstrates elevated EM. However, the integration of radiotherapy with chemotherapy can significantly reduce the EM among male patients aged 40\u201369 years with SEER historical stage as localized and regional.<\/jats:p>","DOI":"10.1007\/s00277-026-06796-6","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:13:35Z","timestamp":1769166815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiotherapy in addition to systemic therapy reduces the early mortality of angioimmunoblastic T-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Yaobin","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoda","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingliang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"6796_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01560-7","volume":"17","author":"EWY Chang","year":"2024","unstructured":"Chang EWY, Tan YH, Chan JY (2024) Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol 17:38","journal-title":"J Hematol Oncol"},{"key":"6796_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01199-0","volume":"14","author":"M Zhu","year":"2024","unstructured":"Zhu M, Li N, Fan L, Wu R, Cao L, Ren Y, Lu C, Zhang L, Cai Y, Shi Y, Lin Z, Lu X, Leng J, Zhong S, Hu X, Huang B, Huang R, Zhou W, Yao D, Wu L, Wu W, Liu Q, Xia P, Chen R, Shi W, Zhang R, Lv S, Wang C, Yu L, Li J, Wang Q, Li K, Jin H (2024) Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed\/refractory angioimmunoblastic T-cell lymphoma. Blood Cancer J 14:218","journal-title":"Blood Cancer J"},{"key":"6796_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1479179","volume":"15","author":"Y Xing","year":"2025","unstructured":"Xing Y, Huang J, Zhang Y, Wang Y, Qi S (2025) Advancing the understanding and management of angioimmunoblastic T-cell lymphoma: insights into its pathogenesis, clinical features, and emerging therapeutic strategies. Front Oncol 15:1479179","journal-title":"Front Oncol"},{"key":"6796_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.27165","volume":"99","author":"SY Ong","year":"2024","unstructured":"Ong SY, Zain JM (2024) Aggressive T-cell lymphomas: 2024: updates on diagnosis, risk stratification, and management. Am J Hematol 99:439\u2013456","journal-title":"Am J Hematol"},{"key":"6796_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G (2020) Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer 20:323\u2013342","journal-title":"Nat Rev Cancer"},{"key":"6796_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03179-5","volume":"43","author":"A Krug","year":"2024","unstructured":"Krug A, Saidane A, Martinello C, Fusil F, Michels A, Buchholz CJ, Ricci JE, Verhoeyen E (2024) In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. J Exp Clin Cancer Res 43:262","journal-title":"J Exp Clin Cancer Res"},{"key":"6796_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood.2020010387","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME, Dlouhy I, Vassallo J, Pileri SA, Inghirami G, Montoto S, Vitolo U, Radford J, Vose JM, Federico M (2021) Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood 138:213\u2013220","journal-title":"Blood"},{"key":"6796_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.18324","volume":"198","author":"Z McQuilten","year":"2022","unstructured":"McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A (2022) Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand myeloma and related diseases registry (MRDR). Br J Haematol 198:830\u2013837","journal-title":"Br J Haematol"},{"key":"6796_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.leukres.2015.02.003","volume":"39","author":"A Hahn","year":"2015","unstructured":"Hahn A, Giri S, Yaghmour G, Martin MG (2015) Early mortality in acute myeloid leukemia. Leuk Res 39:505\u2013509","journal-title":"Leuk Res"},{"key":"6796_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ajh.24107","volume":"90","author":"M Binder","year":"2015","unstructured":"Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK (2015) Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol 90:888\u2013891","journal-title":"Am J Hematol"},{"key":"6796_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2217\/fon-2018-0596","volume":"15","author":"P Dhakal","year":"2019","unstructured":"Dhakal P, Chen B, Giri S, Vose JM, Armitage JO, Bhatt VR (2019) Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma. Future Oncol 15:2113\u20132124","journal-title":"Future Oncol"},{"key":"6796_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/hon.3081","volume":"41","author":"E Cencini","year":"2023","unstructured":"Cencini E, Tucci A, Puccini B, Cavallo F, Luminari S, Usai SV, Fabbri A, Pennese E, Marino D, Zilioli VR, Balzarotti M, Petrucci L, Tafuri A, Arcari A, Botto B, Zanni M, Hohaus S, Sartori R, Merli M, Gini G, Al Essa W, Musurca G, Tani M, Nassi L, Daffini R, Mammi C, Marcheselli L, Bocchia M, Spina M, Merli F (2023) The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana linfomi. Hematol Oncol 41:78\u201387","journal-title":"Hematol Oncol"},{"key":"6796_CR13","first-page":"1480","volume":"109","author":"JX Wei","year":"2024","unstructured":"Wei JX, Shastri A, Sica RA, Mantzaris I, Kornblum N, Shah U, Janakiram M, Gritsman K, Verma A, Goldfinger M, Cooper D, Shah N (2024) Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis. Haematologica 109:1480\u20131486","journal-title":"Haematologica"},{"key":"6796_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jnci\/djac206","volume":"115","author":"AM Berkman","year":"2023","unstructured":"Berkman AM, Andersen CR, Hildebrandt MAT, Livingston JA, Green AL, Puthenpura V, Peterson SK, Milam J, Miller KA, Freyer DR, Roth ME (2023) Risk of early death in adolescents and young adults with cancer: a population-based study. J Natl Cancer Inst 115:447\u2013455","journal-title":"J Natl Cancer Inst"},{"key":"6796_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1200\/JOP.18.00511","volume":"15","author":"AJ Moskowitz","year":"2019","unstructured":"Moskowitz AJ (2019) Practical treatment approach for angioimmunoblastic T-cell lymphoma. J Oncol Pract 15:137\u2013143","journal-title":"J Oncol Pract"},{"key":"6796_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41568-021-00348-y","volume":"21","author":"S Haupt","year":"2021","unstructured":"Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y (2021) Sex disparities matter in cancer development and therapy. Nat Rev Cancer 21:393\u2013407","journal-title":"Nat Rev Cancer"},{"key":"6796_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.immuni.2022.05.012","volume":"55","author":"C Yang","year":"2022","unstructured":"Yang C, Jin J, Yang Y, Sun H, Wu L, Shen M, Hong X, Li W, Lu L, Cao D, Wang X, Sun J, Ye Y, Su B, Deng L (2022) Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity. Immunity 55:1268\u20131283.e1269","journal-title":"Immunity"},{"key":"6796_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100001","volume":"6","author":"K Vanura","year":"2021","unstructured":"Vanura K (2021) Sex as decisive variable in lymphoid neoplasms-an update. ESMO Open 6:100001","journal-title":"ESMO Open"},{"key":"6796_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46945-x","volume":"15","author":"AV Kammula","year":"2024","unstructured":"Kammula AV, Sch\u00e4ffer AA, Rajagopal PS, Kurzrock R, Ruppin E (2024) Outcome differences by sex in oncology clinical trials. Nat Commun 15:2608","journal-title":"Nat Commun"},{"key":"6796_CR20","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/jcph.268","volume":"54","author":"H Struemper","year":"2014","unstructured":"Struemper H, Sale M, Patel BR, \u00d8stergaard M, \u00d6sterborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC (2014) Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol 54:818\u2013827","journal-title":"J Clin Pharmacol"},{"key":"6796_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192392","author":"A Allegra","year":"2023","unstructured":"Allegra A, Caserta S, Mirabile G, Gangemi S (2023) Aging and age-related epigenetic drift in the pathogenesis of leukemia and lymphomas: new therapeutic targets. Cells. https:\/\/doi.org\/10.3390\/cells12192392","journal-title":"Cells"},{"key":"6796_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ, Weisenburger DD, Armitage JO, Mounier N, Vose JM (2013) Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31:240\u2013246","journal-title":"J Clin Oncol"},{"key":"6796_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.607145","volume":"11","author":"Z Chen","year":"2021","unstructured":"Chen Z, Huang H, Li X, Fang X, Wang Z, Hong H, Zhang Z, Cai Q, Li Z, Chen M, Yao Y, Pan F, Chen L, Lin T (2021) Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol 11:607145","journal-title":"Front Oncol"},{"key":"6796_CR24","first-page":"1163","volume":"109","author":"FO Meeuwes","year":"2024","unstructured":"Meeuwes FO, Brink M, Plattel W, Van der Poel MWM, Kersten MJ, Wondergem M, B\u00f6hmer L, Woei AJF, Visser O, Oostvogels R, Jansen PM, Neelis KJ, Crijns APG, Dani\u00ebls LA, Snijders TJF, Vermaat JSP, Huls GA, Nijland M (2024) Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands. Haematologica 109:1163\u20131170","journal-title":"Haematologica"},{"key":"6796_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.978608","volume":"12","author":"M Yuan","year":"2022","unstructured":"Yuan M, Zhai Y, Hui Z (2022) Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment. Front Oncol 12:978608","journal-title":"Front Oncol"},{"key":"6796_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32598","volume":"10","author":"Z Guo","year":"2024","unstructured":"Guo Z, Lei L, Zhang Z, Du M, Chen Z (2024) The potential of vascular normalization for sensitization to radiotherapy. Heliyon 10:e32598","journal-title":"Heliyon"},{"key":"6796_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao WL, Xiong J, Kwong YL (2022) How we treat NK\/T-cell lymphomas. J Hematol Oncol 15:74","journal-title":"J Hematol Oncol"},{"key":"6796_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.648637","volume":"11","author":"YJ Hua","year":"2021","unstructured":"Hua YJ, Ou-Yang YF, Zou X, Xia L, Luo DH, Chen MY (2021) The effect of prolonged duration of intensity modulated radiotherapy for nasopharyngeal carcinoma. Front Oncol 11:648637","journal-title":"Front Oncol"},{"key":"6796_CR29","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.26270","volume":"96","author":"JM Zain","year":"2021","unstructured":"Zain JM, Hanona P (2021) Aggressive T-cell lymphomas: 2021 updates on diagnosis, risk stratification and management. Am J Hematol 96:1027\u20131046","journal-title":"Am J Hematol"},{"key":"6796_CR30","first-page":"e74","volume":"32","author":"NPC Zing","year":"2018","unstructured":"Zing NPC, Fischer T, Zain J, Federico M, Rosen ST (2018) Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice-part 1: PTCL-NOS, FTCL, AITL, ALCL. Oncology (Williston Park) 32:e74\u2013e82","journal-title":"Oncology (Williston Park)"},{"key":"6796_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue D, McBride WH (2015) Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 12:527\u2013540","journal-title":"Nat Rev Clin Oncol"},{"key":"6796_CR32","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/bloodadvances.2022007425","volume":"6","author":"N Shafagati","year":"2022","unstructured":"Shafagati N, Koh MJ, Boussi L, Park HJ, Stuver R, Bain P, Foss FM, Shen C, Jain S (2022) Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis. Blood Adv 6:4740\u20134762","journal-title":"Blood Adv"},{"key":"6796_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06419-w","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Yang C, Xie L, Shi F, Tang M, Luo X, Liu N, Hu X, Zhu Y, Bode AM, Gao Q, Zhou J, Fan J, Li X, Cao Y (2024) CYLD induces high oxidative stress and DNA damage through class i HDACs to promote radiosensitivity in nasopharyngeal carcinoma. Cell Death Dis 15:95","journal-title":"Cell Death Dis"},{"key":"6796_CR34","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1038\/s41598-023-32509-4","volume":"13","author":"ABA Laranjeira","year":"2023","unstructured":"Laranjeira ABA, Hollingshead MG, Nguyen D, Kinders RJ, Doroshow JH, Yang SX (2023) DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. Sci Rep 13:5964","journal-title":"Sci Rep"},{"key":"6796_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409\u2013425","journal-title":"Nat Rev Cancer"},{"key":"6796_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151:159\u2013166","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06796-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06796-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:01:06Z","timestamp":1781629266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06796-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6796"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06796-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the SEER data public, the approval of the ethics committee is not required. The SEER data has hidden the patient\u2019s identity information, so the patient\u2019s informed consent is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}